Nefiracetam to enhance cognitive abilities Unlike, for example, modafinil, which was developed to help people suffering from narcolepsy and other sleep disorders, where cognitive function is not so important. Nefiracetam belongs to the racetam family and shows similarities to aniracetam. It affects both GABA receptors and choline receptors. Its long-term use has both neuroprotective and nootropic effects, as shown in animal studies. CAUTION: Nefiracetam can cause serious kidney problems. People with any kidney problems should not use nefiracetam! Nefiracetam does not have its full effect from the first dose, like PRL-8-53 or phenylpiracetam. It should be taken for at least a few days if you want to improve your cognitive function and memory. It is assumed that the minimum period of taking the drug is 7 days. Only after this time does its effect reach its full potential. This has been proven in animal studies, as well as in some

NACET is the N-Acetyl-Cysteine ethyl esther, which is the precursor to glutathione, the single most powerful antioxidant naturally occurring in human body. Thanks to its ethyl esther form, it is more lipophilic (fat-soluble) than the original NAC, which allows for better absorption through the lipid membranes of cells, making it is up to 20 times more bioavailable, which translates into more potent antioxidant effects. By increasing glutathione levels, NACET helps protect cells from oxidative damage, which is important for maintaining cellular health and preventing the damage related to aging. It is vital for supporting the detoxification process in the liver; in fact, NAC has long been used in the treatment of acetaminophen poisoning. Apart from being a precursor to glutathione, NAC exhibits antioxidant properties of its own, directly scavenging free radicals. NACET, through its conversion to NAC, may influence the levels of various neurotransmitters in the brain. It is believed

Tranylcypromine is among the most effective drugs used to treat major depressive disorder, including atypical depression, treatment-resistant depression, treatment-resistant social anxiety disorder, with demonstrated efficiency in the treatment of obsessive-compulsive disease (OCD) and panic disorder.  Multiple studies provide evidence for the efficacy and safety of tranylcypromine in bipolar depression. Moreover it has proven superior to lamotrigine and imipramine. While chemically, it is an amphetamine derivative, pharmacologically, it acts as a nonselective, irreversible monoaminoxidase inhibitor (MAOI) with a slight preference for MAO-B. Generally speaking, MAO-A is primarily involved in the breakdown of serotonin, norepinephrine, and dopamine. MAO-B mainly metabolizes dopamine. As nonselective MAOI, tranylcypromine prevents both monoaminoxidase enzymes from degrading the previously mentioned neurotransmitters, however, more readily so in case of the latter. This property, together with weak dopamine and norepinephrine releasing action presumably amounts to energizing effects of tranylcypromine and its capacity to alleviate anhedonia. In a double-blind, cross-over study